Parabilis Medicines, Inc.’s IPO spotlights Helicon peptide cancer drugs like zolucatetide, plus Regeneron’s $125M backing & ...
(NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2 trial evaluating Lynozyfic® (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, ...
Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced ...
New TRIMEDX-AIQ™ conversational capability helps technicians quickly find troubleshooting steps by analyzing location data, ...
FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced a strategic partnership with mTuitive, a leading provider of synoptic ...
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at ...
Drug developers have delivered promising news in the fields of cancer, cardioprotection, delirium and motor system atrophy.
Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at ...
Not all AI is created clinical; Wolters Kluwer experts stress clinician-led development for reliable medication intelligence ...
Australia’s Therapeutic Goods Administration (TGA) has released guidance on manufacturing, supplying, and advertising ...
AI can augment oncology nursing through symptom triage support, trial matching, care plan personalization, pharmacogenomics ...
Ten years of independent contributions across global health data systems, pharmaceutical access policy in sub-Saharan Africa, and peer reviewed scientific research place Oloko at the center of the mos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results